HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial.

Authors:
  • MBM. Berger
    M. Berger
  • CHC. Hoffmann
    C. Hoffmann
  • JSJ. M. Siehl
    J. M. Siehl
  • TWT. Wolf
    T. Wolf
  • JRJ. Rockstroh
    J. Rockstroh
  • GFG. Fätkenheuer
    G. Fätkenheuer
  • KAK. Arastéh
    K. Arastéh
  • FMF. A. Mosthaf
    F. A. Mosthaf
  • CWC. Wyen
    C. Wyen
  • GGGerman HIV-related Lymphoma Study Group
    German HIV-related Lymphoma Study Group

Abstract
8035 Background: The outcome of patients (pts) with HIV-HL has improved since the introduction of highly active antiretroviral therapy (HAART). The current trial was initiated to investigate a risk adapted treatment strategy in pts with HIV-HL as established in HIV-negative pts with HL. Methods: Pts were planned to receive 2x ABVD + 30 Gy involved field (IF) radiation for early stage (ES) favourable HL (stage I/II without risk factors), 4x BEACOPP baseline + 30 Gy IF for ES unfavourable HL (extranodal involvement, large mediastinal mass, ≥ 3 lymph node areas involved), and 6-8 × BEACOPP baseline for advanced stage HL. BEACOPP should be replaced by ABVD in pts with far advanced HIV-infection. HAART was given concomitantly with chemotherapy. The primary endpoint was tolerability and treatment related mortality. Secondary endpoints include event free survival (EFS) and overall survival (OS). Results: 93 pts (7 females) were included in the trial. 18/93 pts (19%) had ES favourable HL, 13 (14%) ES unfavourable HL, and 62 (67%) advanced stage HL. 23/87 pts (26%) had a prior AIDS defining illness. The median CD4 count at HL diagnosis was 212/μ l. Grade 3/4 toxicity occurred in 69% under ABVD and 79% under BEACOPP. 4 pts with advanced stage HL died of neutropenic sepsis after the first, seventh (n=2) and eighth course of BEACOPP, respectively. So far response data are available from 78 pts. After a median follow-up of 13.5 months 19/19 pts (100%) with ES favourable HL and 11/11 pts (100%) with ES unfavourable HL achieved a CR/CRu. In pts with advanced HL the CR/CRu rate was 83% (40/48). Of 5 pts having relapsed 2 received an autologous stem cell transplant resulting in a second remission. 7 of 93 pts (8%) have died. Apart from neutropenic sepsis causes of death were progressive HL (n=2) and progressive HIV-infection (PML, n=1). The 12-months OS of the entire study population is 88.3%. EFS and OS are significantly longer in pts with ES HL than in advanced stage HL (p=0.021 and 0.047, respectively). Conclusions: In pts with HIV-HL risk-adapted CT and concomitant HAART is feasible and effective. However, pts must closely be monitored for neutropenic infections. These data suggest that the prognosis of HIV-HD may approach results achieved in the HIV-negative population with HL.